Clinical Trials
Lytix Biopharma has completed multiple Phase 2 trials demonstrating the safety and efficacy of our oncolytic molecule platform. Explore our ongoing clinical programs below.
Current Studies
NeoLIPA Study
Investigator-initiated Phase 2 study at Oslo University Hospital
Neoadjuvant Ruxotemitide + Pembrolizumab in Resectable Melanoma
This study is exploring neo-adjuvant ruxotemitide (administered before surgery) in combination with standard of care pembrolizumab (KEYTRUDA®) in patients with resectable melanoma.
The objective is to demonstrate that ruxotemitide improves outcomes in these patients and prevents disease recurrence.
Verrica Phase 2
Partner-sponsored study in basal cell carcinoma
51%
Complete Response
97%
Clinical Response
Ruxotemitide (VP-315) in Basal Cell Carcinoma
Verrica has generated impressive Phase 2 data demonstrating a 51% complete response rate and clinical responses in 97% of patients with significant reduction of tumor size.
Patient biopsies showed significant increases in CD4+, CD8+ T cells, and B-cells, indicating strong recruitment of effector immune populations into the tumor, demonstrating the ability of ruxotemitide to reprogram the tumor microenvironment.
Explore Our Full Pipeline
Discover our complete portfolio of oncolytic molecule therapies in development.